Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 23Pancreatic Neoplasms 10Colonic Neoplasms 8Stomach Neoplasms 7Esophageal Neoplasms 7Rectal Neoplasms 5Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Adenocarcinoma Of Esophagus 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Cholangiocarcinoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Neoplasms 3Endometrial Neoplasms 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Melanoma 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Urothelial Carcinoma of the Bladder 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Small Bowel Adenocarcinoma 1Sarcoma, Ewing 1

Interventions

Specimen Handling 3fludarabine 2aldesleukin 2Sunitinib 2Fluorouracil 2Cyclophosphamide 2Bevacizumab 2trastuzumab deruxtecan 1sodium propionate 1semaglutide 1repotrectinib 1patritumab deruxtecan 1isosorbide-5-mononitrate 1fludarabine phosphate 1dehydroftorafur 1Tomography, X-Ray Computed 1Radiosurgery 1Positron-Emission Tomography 1Photography 1Pemetrexed 1Pafolacianine 1Memantine 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Leucovorin 1Isosorbide 1Irinotecan 1Interleukin-2 1IDRX-42 1High-Intensity Interval Training 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × Fluorouracil × 30 days × Clear all
NCT03303495 2026-06-05

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

Sun Yat-sen University

Phase 3 Recruiting
280 enrolled
Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07456852 2026-06-02

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

Mayo Clinic

Phase 1/2 Recruiting
60 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡